Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007

Journal of Bone and Mineral Research

Volumn 26, Issue 3, 2011, Pages 553-560

  Wang, Zhong ^a   Bhattacharyya, Timothy ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Aging; Bisphosphonates; Bone; Osteoporosis; Population Studies

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

AGED; ARTICLE; FEMALE; FEMUR NECK FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; FRAGILITY FRACTURE; GENDER; HUMAN; INCIDENCE; MALE; OSTEOPOROSIS; POSTMENOPAUSE; PREVALENCE; UNITED STATES;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; DIPHOSPHONATES; FEMALE; HIP FRACTURES; HUMANS; INCIDENCE; MALE; REGRESSION ANALYSIS; UNITED STATES;

EID: 79951819873     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.233     Document Type: Article

References (37)

1. Centers for Disease Control and Prevention.; accessed on March 22, 2010.
2. Leibson CL, Tosteson AN, Gabriel SE, Ransom JE, Melton LJ,. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc. 2002; 50: 1644-1650. (Pubitemid 35192535)
3. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001; 285: 785-795.
4. Stafford RS, Drieling RL, Hersh AL,. National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. Arch Intern Med. 2004; 164: 1525-1530. (Pubitemid 38970472)
5. Leslie WD, O'Donnell S, Jean S, et al. Trends in hip fracture rates in Canada. JAMA. 2009; 302: 883-889.
6. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB,. Incidence and Mortality of Hip Fractures in the United States. JAMA. 2009; 302: 1573-1579.
7. Michelson JD, Myers A, Jinnah R, Cox Q, Van Natta M,. Epidemiology of hip fractures among the elderly. Risk factors for fracture type. Clin Orthop Relat Res (311). 1995; 129-135.
8. Schneider JP,. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics. 2006; 61: 31-33. (Pubitemid 43134037)
9. Armamento-Villareal R, Napoli N, Panwar V, Novack D,. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med. 2006; 355: 2048-2050. (Pubitemid 44708036)
10. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007; 89: 349-353. (Pubitemid 46563912)
11. Imai K, Yamamoto S, Anamizu Y, Horiuchi T,. Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy. J Bone Miner Metab. 2007; 25: 333-336. (Pubitemid 47283272)
12. Cheung RK, Leung KK, Lee KC, Chow TC,. Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J. 2007; 13: 485-489. (Pubitemid 351206686)
13. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS,. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008; 39: 224-231.
14. Lenart BA, Lorich DG, Lane JM,. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008; 358: 1304-1306. (Pubitemid 351439247)
15. Visekruna M, Wilson D, McKiernan FE,. Severely Suppressed Bone Turnover and Atypical Skeletal Fragility. J Clin Endocrinol Metab. 2008; 93: 2948-2952.
16. Capeci CM, Tejwani NC,. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am. 2009; 91: 2556-2561.
17. Sayed-Noor AS, Sjoden GO,. Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res. 2009; 467: 1921-1926.
18. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY,. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005; 90: 1294-1301. (Pubitemid 40463979)
19. Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010; 362: 1761-1771.
20. Abrahamsen B, Eiken P, Eastell R,. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009; 24: 1095-1102.
21. Nieves JW, Bilezikian JP, Lane JM, et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int. 2010; 21: 399-408.
22. Elixhauser A, Steiner C, Harris DR, Coffey RM,. Comorbidity measures for use with administrative data. Med Care. 1998; 36: 8-27. (Pubitemid 128456396)
23. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C,. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000; 15: 993-1000. (Pubitemid 30350061)
24. Yang YX, Lewis JD, Epstein S, Metz DC,. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006; 296: 2947-2953. (Pubitemid 46021498)
25. Wang PS, Solomon DH, Mogun H, Avorn J,. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA. 2000; 283: 3211-3216. (Pubitemid 30422038)
26. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H,. HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 2000; 283: 3205-3210. (Pubitemid 30422037)
27. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR,. Use of beta-blockers and risk of fractures. JAMA. 2004; 292: 1326-1332.
28. Anderson RN, Rosenberg HM,. Age standardization of death rates: implementation of the year 2000 standard. Natl Vital Stat Rep. 1998; 47: 1-16 20.
29. Kim HJ, Fay MP, Feuer EJ, Midthune DN,. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000; 19: 335-351. (Pubitemid 30070608)
30. Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009; 20: 1353-1362.
31. Abelson A, Ringe JD, Gold DT, Lange JL, Thomas T,. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates. Osteoporos Int. 2010; 21: 1021-1029.
32. HCUP Methods Series. accessed on March 02, 2010.
33. Grijalva CG, Nuorti JP, Zhu Y, Griffin MR,. Increasing incidence of empyema complicating childhood community-acquired pneumonia in the United States. Clin Infect Dis. 2010; 50: 805-8813.
34. Gehlbach SH, Avrunin JS, Puleo E,. Trends in hospital care for hip fractures. Osteoporos Int. 2007; 18: 585-591. (Pubitemid 46525536)
35. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG,. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008; 22: 346-350. (Pubitemid 351630250)
36. Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS,. Unusual mid-shaft fractures during long term bisphosphonate therapy. Clin Endocrinol (Oxf). 2010; 72: 161-168.
37. Shane E,. Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med. 2010; 362: 1825-1827.